Emergent BioSolutions plunges on wider-than-expected Q2 loss

 ** Shares of drugmaker Emergent BioSolutions EBS.N fall 36.2% to $6.3 before the bell

** Late-Tuesday, co reported wider-than-estimated Q2 adj. loss and also widened its 2024 net loss forecast range

** Posted Q2 adj. loss of $2.32/per share vs. analysts' estimates of loss of 95 cents

** The company now sees an adjusted net loss of $115 mln to $75 mln, from $65 mln to $15 mln expected earlier

** Co, however, lifted its FY rev forecast to $1.05-$1.13 bln from $1.0-$1.10 bln

** As of last close, stock up 310.8% YTD

https://www.xm.com/research/markets/allNews/reuters/emergent-biosolutions-plunges-on-widerthanexpected-q2-loss-53900340